Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6639-E6648. doi: 10.1073/pnas.1606050113. Epub 2016 Oct 4.

Abstract

Natural infections expose the immune system to escalating antigen and inflammation over days to weeks, whereas nonlive vaccines are single bolus events. We explored whether the immune system responds optimally to antigen kinetics most similar to replicating infections, rather than a bolus dose. Using HIV antigens, we found that administering a given total dose of antigen and adjuvant over 1-2 wk through repeated injections or osmotic pumps enhanced humoral responses, with exponentially increasing (exp-inc) dosing profiles eliciting >10-fold increases in antibody production relative to bolus vaccination post prime. Computational modeling of the germinal center response suggested that antigen availability as higher-affinity antibodies evolve enhances antigen capture in lymph nodes. Consistent with these predictions, we found that exp-inc dosing led to prolonged antigen retention in lymph nodes and increased Tfh cell and germinal center B-cell numbers. Thus, regulating the antigen and adjuvant kinetics may enable increased vaccine potency.

Keywords: antigen retention; computational immunology; germinal center formation; humoral response; vaccination kinetics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / administration & dosage*
  • Adjuvants, Immunologic / administration & dosage
  • Animals
  • Antibodies, Viral / biosynthesis*
  • Antibody Affinity
  • B-Lymphocytes / cytology
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / immunology
  • CHO Cells
  • Cricetulus
  • Drug Administration Schedule
  • Female
  • Germinal Center / cytology
  • Germinal Center / drug effects*
  • Germinal Center / immunology
  • HEK293 Cells
  • HIV Envelope Protein gp120 / administration & dosage*
  • HIV Envelope Protein gp120 / biosynthesis
  • Humans
  • Immunogenicity, Vaccine
  • Infusion Pumps, Implantable
  • Lipid A / administration & dosage
  • Lipid A / analogs & derivatives
  • Mice
  • Mice, Inbred C57BL
  • Osmotic Pressure
  • Recombinant Fusion Proteins / administration & dosage
  • Recombinant Fusion Proteins / biosynthesis
  • Vaccination / instrumentation
  • Vaccination / methods*

Substances

  • AIDS Vaccines
  • Adjuvants, Immunologic
  • Antibodies, Viral
  • HIV Envelope Protein gp120
  • Lipid A
  • Recombinant Fusion Proteins
  • gp120 protein, Human immunodeficiency virus 1
  • monophosphoryl lipid A